A urinary test for pulmonary arterial hypertension?

American Journal of Respiratory and Critical Care Medicine

Volumn 172, Issue 3, 2005, Pages 262-263

  Lara, Abigail R ^a   Erzurum, Serpil C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BOSENTAN; ENDOTHELIN A RECEPTOR ANTAGONIST; NITRIC OXIDE; NITROGEN OXIDE;

AIRFLOW; EDITORIAL; FLOW RATE; HUMAN; KIDNEY CLEARANCE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; METABOLIC RATE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTEMIC VASCULAR RESISTANCE; URINALYSIS; URINARY EXCRETION;

ANTIHYPERTENSIVE AGENTS; ARGININE; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; PULMONARY ARTERY; SULFONAMIDES;

EID: 22644439895     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.2505009     Document Type: Editorial

References (16)

1. Fagan KA, Fouty BW, Tyler RC, Morris KG Jr, Hepler LK, Sato K, LeCras TD, Abman SH, Weinberger HD, Huang PL, et al. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia. J Clin Invest 1999;103:291-299.
2. Steudel W, Scherrer-Crosbie M, Bloch KD, Weimann J, Huang PL, Jones RC, Picard MH, Zapol WM. Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3. J Clin Invest 1998;101:2468-2477.
3. Girgis RE, Champion HC, Diette GB, Johns RA, Permutt S, Sylvester JT. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med 2005;172:352-357.
4. Ozkan M, Dweik RA, Laskowski D, Arroliga AC, Erzurum SC. High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy. Lung 2001;179:233-243.
5. Ikeda U, Yamamoto K. Maeda Y, Shimpo M, Kanbe T, Shimada K. Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells. Hypertension 1997;29:65-69.
6. Wedgwood S, Black SM. Endothelin-1 decreases endothelial NOS expression and activity through ETA receptor-mediated generation of hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol 2005;288:L480-L487.
7. Bowers R, Cool C, Murphy RC, Tuder RM, Hopken MW, Flores SC, Voelkel NF. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004;169:764-769.
8. Machado RF, Londhe Nerkar MV, Dweik RA, Hammel J, Janocha A, Pyle J, Laskowski D, Jennings C, Arroliga AC, Erzurum SC. Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. Free Radic Biol Med 2004;37:1010-1017.
9. Green LC, Ruiz de Luzuriaga K, Wagner DA, Rand W, Istfan N, Young VR, Tannenbaum SR. Nitrate biosynthesis in man. Proc Natl Acad Sci USA 1981;78:7764-7768.
10. Castillo L. Sources of nitrates and nitrites in neonates with sepsis. J Pediatr 1994;124:488.
11. Demoncheaux EA, Higenbottam TW, Kiely DG, Wong JM, Wharton S, Varcoe R, Siddons T, Spivey AC, Hall K, Gize AP. Decreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension. J Vasc Res 2005;42:133-136.
12. Pearson DL, Dawling S, Walsh WF, Haines JL, Christman BW, Bazyk A, Scott N, Summar ML. Neonatal pulmonary hypertension-urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. N Engl J Med 2001;344:1832-1838.
13. Boger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003;59:824-833.
14. Morris CR, Morris SM Jr, Hagar W, Van Warmerdam J, Claster S, Kepka-Lenhart D, Machado L, Kuypers FA, Vichinsky EP. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003;168:63-69.
15. Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, Goggans T, Thunnissen FB, Farver C, Hazen SL, Jennings C, et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 2004;18:1746-1748.
16. Lin EE, Hunter CJ, Dejam A, Machado R, Martyr S, Hunter L, Gladwin MT, Kato GJ. Level of soluble adhesion molecules in patients with sickle cell disease is associated with pulmonary hypertension and predicts impaired vascular reactivity [abstract]. Proc Am Thorac Soc 2005;2: A196.